Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma — Stella

Home/EBV-Related Hodgkin Lymphoma/EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma

View on ClinicalTrials.gov

Recruiting

Back to EBV-Related Hodgkin Lymphoma trials

EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(2 sites)

United States

Houston Methodist Hospital, Houston, Texas

Texas Children's Hospital, Houston, Texas

Key details

Phase

Early testing

Sponsor

Baylor College of Medicine

Collaborators

The Methodist Hospital Research Institute, National Cancer Institute (NCI)

Enrollment target

~52 participants

Started

October 2022

Primary completion

April 2026

This trial's estimated completion date has passed — the record may not be fully up to date.

Last updated December 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.